KRAS and neoplasm: In the 20020408 study of panitumumab plus BSC vs BSC alone, PFS was significantly improved in patients with wild-type KRAS exon 2 tumours (HR=0.45; 95% CI=0.34–0.59) (Amado et al, 2008), and this treatment effect was greater in retrospective analysis in the wild-type RAS population (HR=0.39; 95% CI=0.27–0.56) (Peeters et al, 2013).